Skip to main content
👋
Is this profile yours? Take control to keep your details current, set fees, and respond to reviews.
This page is aggregated from public sources. Claim this profile →
Dr Helen Spoudeas
✓ Verified Trust score 92/100 Accepting new patients

Dr

Dr Helen Spoudeas

Paediatrics

4.65 · 18 verified reviews

English
8,830+ Patients seen
6 Years in practice
9 Publications
1 Languages spoken

About

Dr Helen Spoudeas is a Consultant Endocrinologist with two decades of experience in the management and treatment of paediatric endocrine problems at Great Ormond Street Hospital. She is well known for pioneering the first neuroendocrine surveillance and neurorehabilitation of childhood brain injury survivors.

Dr Helen Spoudeas, qualified with MBBS (London) from St Bartholomew's Hospital, in 1981. Having initially entered a GP training scheme and obtained my Obstetric diploma (DRCOG) in 1983, I subsequently pursued a career in paediatrics. In 1985 I obtained my full

paediatric qualification, MRCP (UK) and began endocrine training in 1988 with

clinical research at the Middlesex Hospital (encompassed in UCLH) as a senior

registrar. I worked in all areas of clinical paediatric endocrinology at the

tertiary service at UCLH from 1988 until 1999 - it being merged with the Great

Ormond Street site in 1996 - and was awarded my doctorate (MD London) on the neuroendocrine

disturbance after brain tumours in childhood - in 1995. I achieved dual accreditation

with certificates of speciality training (CCST) in both paediatrics and paediatric endocrinology in 1996. In 1999, I was elected FRCPCH, and also elected FRCP in 2000.

Clinical Leadership Roles

In January 1999, I was promoted to consultant paediatric and adolescent endocrinologist at the two NHS trusts in a split site service. This seamless transition service sees all endocrine disorders in infants and children up to 13 to 16 years of age at Great Ormond Street Hospital (GOSH), and adolescents aged 13 to 20 years at University College Hospital (UCH). The split-site service is by

far the largest paediatric endocrine service in the United Kingdom and we are now a team of 9 endocrine consultants with differing subspecialist interests receiving both tertiary and quaternary patient referrals from all the UK and abroad in commissioned NHS and international private patients. In supporting other similar specially commissioned medical and surgical specialities at GOSH, we see some of the most complex, rarest and youngest cases nationally.

Within this large service, for 20 years until 0ctober 2019, I created, developed and led the first and largest, nationally recognised innovative ‘one-stop' neuroendocrine service for children surviving

cancers and then, as more children survived, more specifically, brain tumours. I delivered care personally to over one thousand children and young adults surviving brain tumours across the two

sites. From 2010, I pioneered a virtual paediatric multi-disciplinary national interest group for rare hypothalamo-pituitary (HPAT) brain tumours. These endeavours aimed to create services for

new rare patient cohorts now surviving increasingly intensive therapies, to understand the relative contributions of disease and treatment on later health-related morbidity and brain injury, setting standards nationally with multiprofessional collaboration (encompassing specialist fertility, nephrology, neuropsychology, neuro-rehabilitation, endocrinology, neuro-ophthalmology,) and hailed as a ‘beacon' service in 2005 NICE- approved DoH guidance.

From 2003 to 2020, I was the nominated paediatric endocrine society (BSPED) stakeholder representative for national paediatric neurosurgical and oncology service issues and developed collaborative clinical research trials in neuroncology across Europe with colleagues from the international oncology society (SIOP), as well as the first national paediatric guidelines on rare endocrine tumours with the UK oncology society (CCLG). Since October 2019, when I retired from

full time NHS work, I have continued to run a busy private general endocrine /adolescent practice and returned part time to the NHS in a supervisory support role to the pituitary tumour service at GOSH. I remain a core member of the GOSH neuro oncology and HPAT multi-disciplinary teams .

Maintaining Excellence for Patient Benefit

Since 2019, I am actively supporting further service development at GOSH with my successor, especially to gain formal NHSE recognition of national HPAT MDT and to implement the 3 joint endocrine oncology, RCPCH-endorsed national pituitary tumour guidelines for children

under 19 years of age, that I led from 2013 and finalised in 2020. In March 2020 I launched a national charity, www.successcharity.org.uk Life After Cure, campaigning for better futures for childhood brain tumour survivors, specifically recognising, characterising and rehabilitating their often neglected wider neuroendocrine brain injury, from diagnosis. We aim to partner with like-minded NHS paediatric neuroncology centres to support improved and innovative rehabilitative service interventions, targeted at improving health related quality of survival, mental health, educational and employment outcomes.

Academic and Educational Roles

I have wide postgraduate teaching experience, holding London Deanery and RCPCH regional

speciality paediatric training roles between 2000 and 2009, and subsequently accredited as an educational supervisor of paediatric trainees. Since 1999, I continue to hold an honorary

associate professor post at the Institute of Child Health, London, supervising paediatric endocrinology MSc and PhD students and also publishing peer-reviewed articles in my neuroendocrine field with mulitprofessional colleagues. I am a recognised international speaker on the conference platform and continue to facilitate, foster and enable paediatric and endocrine collaboration for younger colleagues, advocating for closer multiprofessional research and training.

Since 2013, I have chaired a national initiative commissioned by the two foremost societies in paediatric oncology (CCLG) and endocrinology (BSPED) in the UK, to produce RCPCH endorsed

guidance to NIHCE methodology on the management of 8 rare paediatric endocrine tumours (3 pituitary and 5 general). These are incrementally being brought to completion and publication since 2020.

“Evidence-based care tailored to each patient — taking the time to explain options and shared decisions.”

— Dr Helen Spoudeas

Education & training

  1. 2010–2016 MD · Medicine and Surgery
    UAB Barcelona
  2. 2016–2020 Residency · Paediatrics
    Universitat de Barcelona

Career & appointments

  1. 2020-09–2021-08 Junior consultant
    UAB Barcelona Teaching Hospital — Paediatrics

Licenses & insurance

Medical licenses

— Organización Médica Colegial de España (OMC)
#-820709 active · expires 2028-12-31

Board certifications

European Board of Paediatrics
#EB-260C24B0 · issued 2021 · renewal 2031
Malpractice insurance: Generali Healthcare · 3,000,000 EUR coverage · No claims on file

Procedures performed

ProcedureCodeLifetime count
GP consultation 99213 1,853
Annual physical exam 99395 2,875
Vaccination administration 90471 2,083
Minor procedure (skin) 17110 388

Services & pricing

ServiceDurationModalityPrice
New patient consultation (60m) 60 min in_clinic|telemed 180.00 EUR
Follow-up consultation (30m) 30 min in_clinic|telemed|phone 90.00 EUR
Vaccination administration 60 min in_clinic 450.00 EUR
Minor procedure (skin) 90 min in_clinic 180.00 EUR

Office, team & in practice

Helen Spoudeas
HEADSHOT
Helen Spoudeas in consultation
IN OFFICE
Helen Spoudeas with the team
WITH TEAM
Helen Spoudeas at a conference
CONFERENCE

Videos

introduction · 81s
Meet Helen Spoudeas

Research & publications

h-index: 14 · i10: 9

  1. Long-term follow-up of Paediatrics across
    Helen Spoudeas, et al. · European Journal of Medicine, 2026
    DOI: 10.4371/euroclin.2026.0 · PMID: 32419185 · cited by 53
  2. Validation of clinical scoring in Paediatrics
    Helen Spoudeas, et al. · European Journal of Medicine, 2025
    DOI: 10.4949/euroclin.2025.1 · PMID: 33501640 · cited by 167
  3. Long-term follow-up of Paediatrics across
    Helen Spoudeas, et al. · European Journal of Medicine, 2024
    DOI: 10.2386/euroclin.2024.2 · PMID: 38995200 · cited by 105

Invited talks

  • Practical updates in Paediatrics European Annual Congress (Paediatrics) · Vienna · 2024 · invited
  • Single-centre experience in Paediatrics National Society Meeting · · 2023 · oral abstract

Awards & memberships

Awards

  • 🏆 Top-rated Paediatrics — · EuroClinics Patient Choice · 2025 · regional

Society memberships

  • WONCA Europe — Family Doctors — Member · since 2021
  • national college of family doctors — Member · since 2021
  • European Union of Medical Specialists (UEMS) — Member · since 2021

Patient reviews

★ 4.65 18 verified reviews
Bedside Manner
4.70
Knowledge
4.73
Wait Time
4.40
Staff Friendliness
4.67
Ease Of Appointment
4.55
Value For Money
4.57
Would Recommend Pct
92
  • ★ 5 verified visit

    “Very thorough first visit — explained every step. Booking was easy and the staff were welcoming.”

    — Anna B. · 2026-05-15

  • ★ 5 verified visit

    “Took time to listen and reviewed all my previous results. I would absolutely recommend.”

    — Marco V. · 2026-04-14

  • ★ 4 verified visit

    “Professional and knowledgeable. Wait on the day was a bit long, otherwise excellent.”

    — Helena F. · 2026-04-25

Articles by this doctor

  • Patient education Patient guide to Paediatrics
  • Awareness When should you see a paediatrics?

For international patients

Coordinator
Patient liaison · dr.helen.spoudeas@euroclinics.example

Similar specialists

Browse all →